Please enable JavaScript to continue using this application.

Compare $AVTX vs $DSGN | Chartloom

Compare

$AVTX vs $DSGN

Avalo Therapeutics Inc · Design Therapeutics Inc

AVTX

Avalo Therapeutics Inc

DSGN

Design Therapeutics Inc

Compare $AVTX vs $DSGN

Comparing Avalo Therapeutics Inc and Design Therapeutics Inc

AVTXAvalo Therapeutics Inc

DSGNDesign Therapeutics Inc

AVTXAvalo Therapeutics Inc

Market cap

$722M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-86.6%

YTD performance

-19.8%

52W performance

-4.0%

FCF yield

-9.5%

DSGNDesign Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

28.0%

52W performance

67.9%

FCF yield

-7.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVTX

DSGN

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

DSGN

Design Therapeutics Inc

Market Cap

AVTX$722M

DSGN$728M

Enterprise Value

AVTX$639M

DSGN$715M

Price

AVTX$13.65

DSGN$11.65

P/E Ratio

AVTXN/A

DSGNN/A

P/S Ratio

AVTX12,238.73x

DSGN0.00x

EV/Sales

AVTX10,825.47x

DSGN0.00x

EV/EBITDA

AVTX0.00x

DSGN0.00x

P/B Ratio

AVTX1.79x

DSGN3.83x

P/FCF Ratio

AVTXN/A

DSGNN/A

EV/FCF

AVTX-9.35x

DSGN-12.96x

PEG Ratio

AVTXN/A

DSGNN/A

Forward P/E (NTM)

AVTXN/A

DSGNN/A

Forward P/S (NTM)

AVTXN/A

DSGNN/A

Revenue (TTM)

AVTX$59K

DSGN$0

Revenue Growth (YoY)

AVTX-86.6%

DSGNN/A

Forward Rev Growth

AVTX1345.1%

DSGN1360.4%

Gross Margin (TTM)

AVTX242.2%

DSGN0.0%

Operating Margin (TTM)

AVTX0.0%

DSGN0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

DSGN0.0%

Net Margin (TTM)

AVTX-170055.9%

DSGN0.0%

FCF Margin (TTM)

AVTX-115745.8%

DSGNN/A

Net Income (TTM)

AVTX$-100M

DSGN$-71M

FCF (TTM)

AVTX$-68M

DSGN$-55M

EPS (TTM)

AVTX-$2.30

DSGN-$1.13

ROE (TTM)

AVTX-5803.0%

DSGN-3403.0%

ROA (TTM)

AVTX-4822.0%

DSGN-3205.0%

ROIC (TTM)

AVTX-5729.0%

DSGN-3403.0%

Cash

AVTX$85M

DSGN$13M

Debt

AVTX$2M

DSGN$0

Net Cash/Debt

AVTX$83M

DSGN$13M

Current Ratio (TTM)

AVTX19.31x

DSGN18.86x

Quick Ratio (TTM)

AVTX18.95x

DSGN18.61x

Debt/Equity (TTM)

AVTX0.00x

DSGN0.00x

Debt/Assets (TTM)

AVTX0.0%

DSGN0.0%

Interest Coverage (TTM)

AVTXN/A

DSGNN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

DSGN0.00x

Beta

AVTX0.62

DSGN1.72

52W Performance

AVTX-4.0%

DSGN67.9%

YTD Performance

AVTX-19.8%

DSGN28.0%

% from 52W High

AVTX-43.8%

DSGN-32.5%

% from 52W Low

AVTX9.1%

DSGN120.6%

Asset Turnover (TTM)

AVTX0.00x

DSGN0.00x

FCF Yield (TTM)

AVTX-9.5%

DSGN-7.6%

Earnings Yield (TTM)

AVTX-13.9%

DSGN-9.7%

Dividend Yield (TTM)

AVTXN/A

DSGNN/A

Rule of 40

AVTX-115,832.4

DSGN0.0

EV/GP/RG

AVTX1.31

DSGNN/A

Ticker research

View AVTX research View DSGN research

Metric	AVTX Avalo Therapeutics Inc	DSGN Design Therapeutics Inc
Market & Valuation
Market Cap	$722M	$728M
Enterprise Value	$639M	$715M
Price	$13.65	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	0.00x
EV/Sales	10,825.47x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	3.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-12.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$0
Revenue Growth (YoY)	-86.6%	N/A
Forward Rev Growth	1345.1%	1360.4%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	0.0%
Net Margin (TTM)	-170055.9%	0.0%
FCF Margin (TTM)	-115745.8%	N/A
Net Income (TTM)	$-100M	$-71M
FCF (TTM)	$-68M	$-55M
EPS (TTM)	-$2.30	-$1.13
ROE (TTM)	-5803.0%	-3403.0%
ROA (TTM)	-4822.0%	-3205.0%
ROIC (TTM)	-5729.0%	-3403.0%
Financial Health
Cash	$85M	$13M
Debt	$2M	$0
Net Cash/Debt	$83M	$13M
Current Ratio (TTM)	19.31x	18.86x
Quick Ratio (TTM)	18.95x	18.61x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	1.72
52W Performance	-4.0%	67.9%
YTD Performance	-19.8%	28.0%
% from 52W High	-43.8%	-32.5%
% from 52W Low	9.1%	120.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-9.5%	-7.6%
Earnings Yield (TTM)	-13.9%	-9.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	0.0
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View DSGN research

Valuation

P/S Ratio

DSGN

0.00x

AVTX

12,238.73x

EV/FCF

DSGN

-12.96x

AVTX

-9.35x

Growth & revenue

Revenue Growth TTM

AVTX

-86.6%

Forward Revenue Growth

DSGN

1360.4%

AVTX

1345.1%

Profitability & performance

Gross Margin

AVTX

242.2%

DSGN

0.0%

ROE

DSGN

-3403.0%

AVTX

-5803.0%

FCF Yield %

DSGN

-7.6%

AVTX

-9.5%

52-Week Performance

DSGN

67.9%

AVTX

-4.0%

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

DSGN

Design Therapeutics Inc

Market Cap

AVTX$722M

DSGN$728M

Enterprise Value

AVTX$639M

DSGN$715M

Price

AVTX$13.65

DSGN$11.65

P/E Ratio

AVTXN/A

DSGNN/A

P/S Ratio

AVTX12,238.73x

DSGN0.00x

EV/Sales

AVTX10,825.47x

DSGN0.00x

EV/EBITDA

AVTX0.00x

DSGN0.00x

P/B Ratio

AVTX1.79x

DSGN3.83x

P/FCF Ratio

AVTXN/A

DSGNN/A

EV/FCF

AVTX-9.35x

DSGN-12.96x

PEG Ratio

AVTXN/A

DSGNN/A

Forward P/E (NTM)

AVTXN/A

DSGNN/A

Forward P/S (NTM)

AVTXN/A

DSGNN/A

Revenue (TTM)

AVTX$59K

DSGN$0

Revenue Growth (YoY)

AVTX-86.6%

DSGNN/A

Forward Rev Growth

AVTX1345.1%

DSGN1360.4%

Gross Margin (TTM)

AVTX242.2%

DSGN0.0%

Operating Margin (TTM)

AVTX0.0%

DSGN0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

DSGN0.0%

Net Margin (TTM)

AVTX-170055.9%

DSGN0.0%

FCF Margin (TTM)

AVTX-115745.8%

DSGNN/A

Net Income (TTM)

AVTX$-100M

DSGN$-71M

FCF (TTM)

AVTX$-68M

DSGN$-55M

EPS (TTM)

AVTX-$2.30

DSGN-$1.13

ROE (TTM)

AVTX-5803.0%

DSGN-3403.0%

ROA (TTM)

AVTX-4822.0%

DSGN-3205.0%

ROIC (TTM)

AVTX-5729.0%

DSGN-3403.0%

Cash

AVTX$85M

DSGN$13M

Debt

AVTX$2M

DSGN$0

Net Cash/Debt

AVTX$83M

DSGN$13M

Current Ratio (TTM)

AVTX19.31x

DSGN18.86x

Quick Ratio (TTM)

AVTX18.95x

DSGN18.61x

Debt/Equity (TTM)

AVTX0.00x

DSGN0.00x

Debt/Assets (TTM)

AVTX0.0%

DSGN0.0%

Interest Coverage (TTM)

AVTXN/A

DSGNN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

DSGN0.00x

Beta

AVTX0.62

DSGN1.72

52W Performance

AVTX-4.0%

DSGN67.9%

YTD Performance

AVTX-19.8%

DSGN28.0%

% from 52W High

AVTX-43.8%

DSGN-32.5%

% from 52W Low

AVTX9.1%

DSGN120.6%

Asset Turnover (TTM)

AVTX0.00x

DSGN0.00x

FCF Yield (TTM)

AVTX-9.5%

DSGN-7.6%

Earnings Yield (TTM)

AVTX-13.9%

DSGN-9.7%

Dividend Yield (TTM)

AVTXN/A

DSGNN/A

Rule of 40

AVTX-115,832.4

DSGN0.0

EV/GP/RG

AVTX1.31

DSGNN/A

Ticker research

View AVTX research View DSGN research

Metric	AVTX Avalo Therapeutics Inc	DSGN Design Therapeutics Inc
Market & Valuation
Market Cap	$722M	$728M
Enterprise Value	$639M	$715M
Price	$13.65	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	0.00x
EV/Sales	10,825.47x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	3.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-12.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$0
Revenue Growth (YoY)	-86.6%	N/A
Forward Rev Growth	1345.1%	1360.4%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	0.0%
Net Margin (TTM)	-170055.9%	0.0%
FCF Margin (TTM)	-115745.8%	N/A
Net Income (TTM)	$-100M	$-71M
FCF (TTM)	$-68M	$-55M
EPS (TTM)	-$2.30	-$1.13
ROE (TTM)	-5803.0%	-3403.0%
ROA (TTM)	-4822.0%	-3205.0%
ROIC (TTM)	-5729.0%	-3403.0%
Financial Health
Cash	$85M	$13M
Debt	$2M	$0
Net Cash/Debt	$83M	$13M
Current Ratio (TTM)	19.31x	18.86x
Quick Ratio (TTM)	18.95x	18.61x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	1.72
52W Performance	-4.0%	67.9%
YTD Performance	-19.8%	28.0%
% from 52W High	-43.8%	-32.5%
% from 52W Low	9.1%	120.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-9.5%	-7.6%
Earnings Yield (TTM)	-13.9%	-9.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	0.0
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View DSGN research